Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling
NCT ID: NCT01501344
Last Updated: 2012-01-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-01-31
Study Completion Date
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will determine if daily oral intake of 200g of a marketed yogurt with fortified calcium content and a milk basic protein (MBP)80 mg benefits on bone cells activity in postmenopausal women. The efficacy of the product is measured by examining the variation of biochemical markers of bone turnover. MBP 80 is a particular protein contained in milk; it has been added to the yogurt provided for this study. The effects of MBP 80 on the quality of bone tissue have not yet been proven.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of a Probiotic Product on Bone Mineral Density (BMD) in Healthy Women in Early Post-menopausal Phase
NCT02722980
Osteopenia
COMPLETED
NA
Profylactic Treatment for Patients in Risk Osteoporosis
NCT05787808
Osteopenia or Osteoporosis
RECRUITING
NA
Milk Protein and Bone Health in Postmenopausal Women
NCT03701113
Bone and Bones
Osteoporosis Risk
Osteoporosis, Postmenopausal
COMPLETED
NA
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
NCT01478724
Osteoporosis
COMPLETED
PHASE1
Effect of Blueberries on Bone Turnover
NCT02630797
Osteoporosis, Postmenopausal
Bone Loss, Age-related
UNKNOWN
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The morbidity and mortality associated with osteoporotic related fractures is devastating in terms of disability to an individual and cost to the global economy. As the world's population ages, this will present a major public health issue since a larger proportion of women remain undiagnosed and untreated even with the availability of therapies and calcium and vitamin D supplements. Consequently, it remains important to evaluate dairy products (milk, cheese, and yogurt) that can be safely provided as a supplement for bone health in addition to the current pharmacological treatments.
The rationale of this study is to assess the beneficial effect of a daily dietary supplement of MBP 80 mg in a yogurt matrix with fortified calcium content on bone remodelling in healthy early postmenopausal women with neither osteoporosis nor estrogens/progestin therapy.
The rationale of this study is to assess the beneficial effect of a daily dietary supplement of MBP 80 mg in a yogurt matrix with fortified calcium content on bone remodelling in healthy early postmenopausal women with neither osteoporosis nor estrogens/progestin therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Postmenopausal Osteoporosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
200 g yogurt with fortified calcium content and MBP 80 mg
Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Yoplait Asana TM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early postmenopausal women, aged 45-60 yrs old inclusive, with 1-5 yrs since last menses; naturally or surgically menopausal as a result of bilateral oophorectomy. Hysterectomized (≤ 5 yrs) women 50-60 yrs old.
* Lumbar Spine (L.S.;L1-L4) BMD \> 0.772 g/cm2 (T-score of -2.5 on Hologic) and,
* Femoral Neck BMD \> 0.572 g/cm2 (T-score of -2.5 on Hologic) and,
* Total Hip BMD \> 0.637 g/cm2 (T-score of -2.5 on Hologic).
* Subjects must sign the Ethic Committee approved Informed Consent Form before any study procedure is initiated.
* Lumbar Spine (L.S.;L1-L4) BMD \> 0.772 g/cm2 (T-score of -2.5 on Hologic) and,
* Femoral Neck BMD \> 0.572 g/cm2 (T-score of -2.5 on Hologic) and,
* Total Hip BMD \> 0.637 g/cm2 (T-score of -2.5 on Hologic).
* Subjects must sign the Ethic Committee approved Informed Consent Form before any study procedure is initiated.
Exclusion Criteria
* Any intake of calcium and vitamin D supplements including multivitamins, nutritional or dietary supplements of any kind containing calcium and vit D within 3 months prior to screening visit 1A.
* Daily dietary calcium intake \> 600 mg as assessed by the Calcium Intake Calculator (Appendix E).
* Subjects who already suffer from osteoporosis on the basis of a low BMD T-score ≤ - 2.5 at any site or a personal history of fragility fracture after age 40.
* Any past or present use of:
* Bisphosphonate
* PTH or PTH derivatives, eg. teriparatide
* Androgens, anabolic steroids or testosterone
* Tibolone
* Calcitriol
* Strontium ranelate
* Lithium, chronic warfarin or heparin use \> 3 months, anticonvulsants (benzodiazepines are allowed), gonadotrophin-releasing hormone agonists, glitazones.
* Administration of any of the following treatments within the last 3 months prior to screening:
* Glucocorticosteroids (\> 5 mg prednisone equivalent per day for \> 10 days)
* Systemic hormone replacement therapy
* Selective estrogen receptor modulators (SERMs), eg, raloxifene
* Calcitonin
* Any unapproved hormone-like treatment in the opinion of the Principal Investigator (P.I.), i.e. phytoestrogens, isoflavones, etc.
* Antacids, H2 blockers, proton pump inhibitors for \> 10 days
* Iron supplements for \> 10 days
* Any condition or disease that may, according to the P.I., interfere with the evaluation of L.S. and Hip BMD; including but not limited to: advanced scoliosis or extensive lumbar fusion, less than 2 lumbar vertebrae (L1-L4) evaluable for DXA.
* Hyper or hypothyroidism: patients on stable dose of thyroid treatment with normal TSH will be allowed. Lab values for TSH must be normal or slightly abnormal, though clinically non significant in the opinion of the P.I.
* Current hyper or hypoparathyroidism, in the opinion of the P.I.
* Current hypocalcemia, in the opinion of the P.I.
* Vit D insufficiency (25-OH vitamin D level \< 40 nmol/L)
* Significantly impaired renal function hereby defined as an estimated GFR ≤ 60 mL/min/ 1.73 m2 (4-variable MDRD equation).
* Rheumatoid arthritis.
* Paget's disease of bone.
* Any history of cancer within the past 5 years (except for basal cell carcinoma, dermal squamous cell carcinoma with 6 month remission and cervix carcinoma in situ).
* Any bone disease, i.e. osteomalacia or osteogenesis imperfecta.
* Chronic asthma, in the opinion of the P.I.
* Malabsorption syndrome (coeliac disease, inflammatory bowel disease, gastric bypass).
* Height, weight and girth which may preclude accurate DXA measurement; BMI outside ranges between 18.5 and 35 inclusive.
* Variation of more than 2 kg (gain or loss) within 2 months of the Screening.
* Presence of any vertebral fracture on the screening VFA (Vertebral Fracture Assessment) measured by DXA.
* Any previous or ongoing clinically significant illness that, in the opinion of the P.I., could prevent the patient from completing the study.
* Evidence of alcohol or substance abuse within the last 12 months that the P.I. believes would interfere with understanding or completing the study.
* Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
* Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
* Daily dietary calcium intake \> 600 mg as assessed by the Calcium Intake Calculator (Appendix E).
* Subjects who already suffer from osteoporosis on the basis of a low BMD T-score ≤ - 2.5 at any site or a personal history of fragility fracture after age 40.
* Any past or present use of:
* Bisphosphonate
* PTH or PTH derivatives, eg. teriparatide
* Androgens, anabolic steroids or testosterone
* Tibolone
* Calcitriol
* Strontium ranelate
* Lithium, chronic warfarin or heparin use \> 3 months, anticonvulsants (benzodiazepines are allowed), gonadotrophin-releasing hormone agonists, glitazones.
* Administration of any of the following treatments within the last 3 months prior to screening:
* Glucocorticosteroids (\> 5 mg prednisone equivalent per day for \> 10 days)
* Systemic hormone replacement therapy
* Selective estrogen receptor modulators (SERMs), eg, raloxifene
* Calcitonin
* Any unapproved hormone-like treatment in the opinion of the Principal Investigator (P.I.), i.e. phytoestrogens, isoflavones, etc.
* Antacids, H2 blockers, proton pump inhibitors for \> 10 days
* Iron supplements for \> 10 days
* Any condition or disease that may, according to the P.I., interfere with the evaluation of L.S. and Hip BMD; including but not limited to: advanced scoliosis or extensive lumbar fusion, less than 2 lumbar vertebrae (L1-L4) evaluable for DXA.
* Hyper or hypothyroidism: patients on stable dose of thyroid treatment with normal TSH will be allowed. Lab values for TSH must be normal or slightly abnormal, though clinically non significant in the opinion of the P.I.
* Current hyper or hypoparathyroidism, in the opinion of the P.I.
* Current hypocalcemia, in the opinion of the P.I.
* Vit D insufficiency (25-OH vitamin D level \< 40 nmol/L)
* Significantly impaired renal function hereby defined as an estimated GFR ≤ 60 mL/min/ 1.73 m2 (4-variable MDRD equation).
* Rheumatoid arthritis.
* Paget's disease of bone.
* Any history of cancer within the past 5 years (except for basal cell carcinoma, dermal squamous cell carcinoma with 6 month remission and cervix carcinoma in situ).
* Any bone disease, i.e. osteomalacia or osteogenesis imperfecta.
* Chronic asthma, in the opinion of the P.I.
* Malabsorption syndrome (coeliac disease, inflammatory bowel disease, gastric bypass).
* Height, weight and girth which may preclude accurate DXA measurement; BMI outside ranges between 18.5 and 35 inclusive.
* Variation of more than 2 kg (gain or loss) within 2 months of the Screening.
* Presence of any vertebral fracture on the screening VFA (Vertebral Fracture Assessment) measured by DXA.
* Any previous or ongoing clinically significant illness that, in the opinion of the P.I., could prevent the patient from completing the study.
* Evidence of alcohol or substance abuse within the last 12 months that the P.I. believes would interfere with understanding or completing the study.
* Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
* Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
Minimum Eligible Age
45 Years
Maximum Eligible Age
60 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aliments ULTIMA Foods Inc.
INDUSTRY
Sponsor Role
collaborator
Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jacques Brown
Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacques P Brown, M.D.
Role: PRINCIPAL_INVESTIGATOR
G.R.M.O. Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
G.R.M.O. Inc.
Québec, Quebec, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000 Mar 27-29;17(1):1-45.
Reference Type
BACKGROUND
Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998 Mar 12;338(11):736-46. doi: 10.1056/NEJM199803123381107. No abstract available.
Reference Type
BACKGROUND
Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005 Jul 14;353(2):164-71. doi: 10.1056/NEJMcp042092. No abstract available.
Reference Type
BACKGROUND
Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet. 1993 Mar 27;341(8848):797-801. doi: 10.1016/0140-6736(93)90570-7. No abstract available.
Reference Type
BACKGROUND
Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003 Sep;14(9):722-7. doi: 10.1007/s00198-003-1430-3. Epub 2003 Aug 7.
Reference Type
BACKGROUND
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003 May;32(5):468-73. doi: 10.1016/s8756-3282(03)00061-9.
Reference Type
BACKGROUND
Takada Y, Aoe S, Kumegawa M. Whey protein stimulated the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun. 1996 Jun 14;223(2):445-9. doi: 10.1006/bbrc.1996.0913.
Reference Type
BACKGROUND
Matsuoka Y, Serizawa A, Yoshioka T, Yamamura J, Morita Y, Kawakami H, Toba Y, Takada Y, Kumegawa M. Cystatin C in milk basic protein (MBP) and its inhibitory effect on bone resorption in vitro. Biosci Biotechnol Biochem. 2002 Dec;66(12):2531-6. doi: 10.1271/bbb.66.2531.
Reference Type
BACKGROUND
Olsson SL, Ek B, Bjork I. The affinity and kinetics of inhibition of cysteine proteinases by intact recombinant bovine cystatin C. Biochim Biophys Acta. 1999 Jun 15;1432(1):73-81. doi: 10.1016/s0167-4838(99)00090-4.
Reference Type
BACKGROUND
Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun. 1995 Jan 5;206(1):89-96. doi: 10.1006/bbrc.1995.1013.
Reference Type
BACKGROUND
Yamamura J, Morita Y, Takada Y, Kawakami H. The fragments of bovine high molecular weight kininogen promote osteoblast proliferation in vitro. J Biochem. 2006 Dec;140(6):825-30. doi: 10.1093/jb/mvj217. Epub 2006 Oct 28.
Reference Type
BACKGROUND
Uenishi K, Ishida H, Toba Y, Aoe S, Itabashi A, Takada Y. Milk basic protein increases bone mineral density and improves bone metabolism in healthy young women. Osteoporos Int. 2007 Mar;18(3):385-90. doi: 10.1007/s00198-006-0228-5. Epub 2006 Oct 18.
Reference Type
BACKGROUND
Toba Y, Takada Y. [Prevention of osteoporosis by foods and dietary supplements. "Mainichi Hone Kea MBP": A foods for specified health uses (FOSHU) product containing MBP that has an effect to increase bone density]. Clin Calcium. 2006 Oct;16(10):1701-5. Japanese.
Reference Type
BACKGROUND
Takada Y, Kobayashi N, Kato K, Matsuyama H, Yahiro M, Aoe S. Effects of whey protein on calcium and bone metabolism in ovariectomized rats. J Nutr Sci Vitaminol (Tokyo). 1997 Apr;43(2):199-210. doi: 10.3177/jnsv.43.199.
Reference Type
BACKGROUND
Toba Y, Takada Y, Yamamura J, Tanaka M, Matsuoka Y, Kawakami H, Itabashi A, Aoe S, Kumegawa M. Milk basic protein: a novel protective function of milk against osteoporosis. Bone. 2000 Sep;27(3):403-8. doi: 10.1016/s8756-3282(00)00332-x.
Reference Type
BACKGROUND
Kruger CL, Marano KM, Morita Y, Takada Y, Kawakami H, Kobayashi T, Sunaga M, Furukawa M, Kawamura K. Safety evaluation of a milk basic protein fraction. Food Chem Toxicol. 2007 Jul;45(7):1301-7. doi: 10.1016/j.fct.2007.01.017. Epub 2007 Jan 30.
Reference Type
BACKGROUND
Aoe S, Toba Y, Yamamura J, Kawakami H, Yahiro M, Kumegawa M, Itabashi A, Takada Y. Controlled trial of the effects of milk basic protein (MBP) supplementation on bone metabolism in healthy adult women. Biosci Biotechnol Biochem. 2001 Apr;65(4):913-8. doi: 10.1271/bbb.65.913.
Reference Type
BACKGROUND
Yamamura J, Aoe S, Toba Y, Motouri M, Kawakami H, Kumegawa M, Itabashi A, Takada Y. Milk basic protein (MBP) increases radial bone mineral density in healthy adult women. Biosci Biotechnol Biochem. 2002 Mar;66(3):702-4. doi: 10.1271/bbb.66.702.
Reference Type
BACKGROUND
Aoe S, Koyama T, Toba Y, Itabashi A, Takada Y. A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoporos Int. 2005 Dec;16(12):2123-8. doi: 10.1007/s00198-005-2012-3. Epub 2005 Aug 31.
Reference Type
BACKGROUND
Toba Y, Takada Y, Matsuoka Y, Morita Y, Motouri M, Hirai T, Suguri T, Aoe S, Kawakami H, Kumegawa M, Takeuchi A, Itabashi A. Milk basic protein promotes bone formation and suppresses bone resorption in healthy adult men. Biosci Biotechnol Biochem. 2001 Jun;65(6):1353-7. doi: 10.1271/bbb.65.1353.
Reference Type
BACKGROUND
Shatenstein B, Nadon S, Godin C, Ferland G. Development and validation of a food frequency questionnaire. Can J Diet Pract Res. 2005 Summer;66(2):67-75. doi: 10.3148/66.2.2005.67.
Reference Type
BACKGROUND
Shatenstein B, et al. Plausability assessment and quality assurance of Food Frequency Questionnaires completed in studies of diet and health International Conference on Diet and Activity Methods (ICDAM) p. 281-282, 2009.
Reference Type
BACKGROUND
Eating well with Canada's Food Guide (c) 2007
Reference Type
BACKGROUND
Canadian Nutrient File. H.W.C. Bureau of Nutriional Sciences, Editor. 1982.
Reference Type
BACKGROUND
Shatenstein B, et al. (and members of the the Division on Nutrition and Healthy Aging, FRSQ Network on Aging), Dietary intakes of homedwelling elderly Quebecers obtained from a food frequency questionnaire: A pilot study. J Nutre Health & Aging 7(4): 234-235, 2003.
Reference Type
BACKGROUND
Yamamura J, Takada Y, Goto M, Kumegawa M, Aoe S. Bovine milk kininogen fragment 1.2 promotes the proliferation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun. 2000 Mar 16;269(2):628-32. doi: 10.1006/bbrc.2000.2326.
Reference Type
BACKGROUND
Hiddink, J., R. de Bore, and D. Romijin Neth Milk Dairy J 32: p. 80-93, 1978.
Reference Type
BACKGROUND
Takada, Y., et al., Whey protein suppresses the osteoclast-mediated bone resorption and osteoclast cell formation. Int Dairy J 7: 821-825, 1997
Reference Type
BACKGROUND
Takada, Y., et al., Milk whey protein enhances the bone breaking force in ovariectomized rats. Nutr Res 17: 1709-1720, 1997.
Reference Type
BACKGROUND
Kato, K., et al., Milk basic protein enhances the bone strength in ovariectomized rats. J Food Biochem 24:467-478, 2000.
Reference Type
BACKGROUND
Corder, G.W.F., D.I. Nonparametric Statistics for Non-Statisticians: A Step-by-Step Approach. New Jesrsey. Wiley. 2009.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBP-80 and Bone Remodelling
Identifier Type: OTHER
Identifier Source: secondary_id
2010YogA80
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Amorphous Calcium Carbonate Supplementation on Bone Health in Postmenopausal Women With Osteopenia
NCT05810909
COMPLETED
NA
Family Milk Product Two-year Dose-response Study to Enhance Bone Health
NCT02236871
COMPLETED
NA
A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
NCT01857154
UNKNOWN
NA
Nutritional Supplement and Bone Health in Post-Menopausal Women
NCT03337971
COMPLETED
NA
Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health
NCT00698984
COMPLETED
NA
Effect of Consumption of Supplements and Enriched Olive Paste on Bone Metabolism Indices
NCT06135831
COMPLETED
NA
Design and Development of a Novel Food Supplement for Osteoporosis Based on Gut Microbiome Mechanisms
NCT05421819
COMPLETED
NA
Yogurt Supplementation to Alter Bone Biomarkers, the Gut Microbiota and Inflammation in Older Adults
NCT05350579
TERMINATED
NA
Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism
NCT00671944
COMPLETED
PHASE1
Study of the Osteoprotector Effects of a Milk Product Based on Anthocyans and Enriched in Calcium and Vitamin D
NCT00663221
COMPLETED
PHASE2
Milk on Gut Microbiome and Bone Remodeling CTX in Postmenopausal Women
NCT06050018
UNKNOWN
NA
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
NCT03155269
COMPLETED
NA
Encouraging Calcium Absorption and Bone Formation During Early Puberty
NCT00022867
COMPLETED
PHASE1/PHASE2
A Study on the Impact of Calcium on Woman's Vascular Health
NCT01731340
COMPLETED
PHASE4
Optimal Meals to Reduce Bone Resorption in Women With Osteopenia
NCT07056322
NOT_YET_RECRUITING
NA
To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia
NCT02527668
COMPLETED
PHASE2
Kefir on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients
NCT02361372
COMPLETED
NA
The Postprandial Calcium Absorption of a Milk Derived Calcium Permeate - RENEW Acute Study
NCT04550078
COMPLETED
NA
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
NCT00067600
COMPLETED
PHASE1
Parameters of Exercise to Prevent Osteoporosis
NCT04063813
COMPLETED
NA
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
NCT00139685
COMPLETED
PHASE4
Program to Prevent Osteoporosis in Girls
NCT00063024
UNKNOWN
PHASE3
New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
NCT06525688
RECRUITING
The Long-term Effect of Daily Jarlsberg Cheese Intake in Patient With Osteopenia
NCT06358443
COMPLETED
NA
Bone Intake Proteins and Muscle Mass Deficiency in Proximal Femur Fractures
NCT05804604
COMPLETED